literature

HIV mutation literature information.

Drug resistance mutations in HIV provirus are associated with defective proviral genomes with hypermutation.

PMID: 33635848 2021 AIDS (London, England)

Abstract: Certain Apolipoprotein B Editing Complex 3-related DRMs including reverse transcriptase gene mutations M184I, E138K, M230I, G190E and protease gene mutations M46I, D30N were enriched in hypermutated sequences but not in intact sequences or plasma sequences.

HIV Drug Resistance Mutations Detection by Next-Generation Sequencing during Antiretroviral Therapy Interruption in China.

PMID: 33668946 2021 Pathogens (Basel, Switzerland)

Abstract: In 49 patients that followed-up a median 10 months later, HIV drug resistance mutations at >20% frequency such as K103N, M184VI and P225H still existed, but with decreased frequencies.

Discussion: Compared with the baseline, the HIVDR mutations, such as N88D, K65R, Discussion: The minority mutations detected by NGS may have resulted from apolipoprotein B mRNA editing catalytic polypeptide (APOBEC)-mediated G-to-A hypermutation such as E138K, M184I and G190E in RT or spontaneous mutation during viral replication, or from PCR error, which was introduced by error-prone reverse transcriptase or PCR enzymes.

Dolutegravir response in antiretroviral therapy naive and experienced patients with M184V/I: Impact in low-and middle-income settings.

PMID: 33722682 2021 International journal of infectious diseases

Abstract: DISCUSSION: Despite high prevalence of M184V/I in antiretroviral therapy (ART) experienced patients, DTG treatment outcomes will likely not be adversely affected by this mutation.

Abstract: DTG-based regimens have to great extent been effective at maintaining viral suppression in treatment experienced PLWH carrying M184V/I.

Abstract: High genetic barrier to the development of resistance associated with DTG and progressive viral suppression in patients switched to DTG-based therapy with M184V/I, may encourage better DTG outcomes and help in curbing increasing levels of HIV drug resistance in LMICs.

Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study.

PMID: 34397746 2021 Journal of acquired immune deficiency syndromes (1999)

Method: We performed subgroup analyses of the participants with plasma HIV-1 RNA <50 copies/mL at week 24 based on age, sex, baseline NRTI resistance, and specifical

Result: Altogether, 68 participants with baseline NRTI resistance (including 50 with M184V/I) received B/F/TAF during the study and had postswitch virologic data.

Result: At baseline, 13% (44 of 328) in the B/F/TAF group and 16% (26 of 165) in the SBR group had NRTI resistance, including 9% (31 of 328) and 12% (20 of 165) with M184V/I mutations in the B/F/TAF and SBR groups, respectively.

Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients During Lamivudine Plus Dolutegravir Maintenance Therapy in Clinical Practice.

PMID: 34327247 2021 Open forum infectious diseases

Abstract: In this dataset from clinical practice investigating the impact of past nucleoside reverse-transcriptase inhibitor resistance on this strategy, the combination o

Table: M184V/I

Discussion: However, previous observational studies suggested an increased risk of VF during 3TC-based DT when M184V/I was present in combination with a shorter time of viral suppression.

Dolutegravir in the long term in children and adolescents: frequent virological failure but rare acquired genotypic resistance.

PMID: 34369051 2021 HIV medicine

Abstract: M184V/I mutations in the reverse transcriptase gene were newly detected in three people with VF.

HIV-1 Drug Resistance and Genetic Transmission Networks Among MSM Failing Antiretroviral Therapy in South China 2014-2019.

PMID: 34377002 2021 Infection and drug resistance

Abstract: The most common DRMs were M184I/V (42.2%), followed by V179D/E (37.9%) and K65R (27.2%).

Table: M184I/V

Discussion: M184I/V (42.2%) was the most prevalent NRTI-associated mutation, which might be caused by the frequent use of 3TC in ART-experienced patients.

Correlation of HIV-1 drug resistant mutations and virologic failure.

PMID: 34584606 2021 The Pan African medical journal

Introduction: These mutations included M184V, K65R,D67N,K70R,K219Q,Q151M, T215F, M41L, T69N, V75M, M41L, T69N, V75M, D67G, V75M, M184I, T215N, M41LM, T215N, K219N,210W, T215Y as NRT

Table: M184I

Prevalence and factors associated with HIV-1 drug resistance mutations in treatment-experienced patients in Nairobi, Kenya: A cross-sectional study.

PMID: 34622871 2021 Medicine

Abstract: NRTI primary mutations M184 V/I and K65R/E/N were found in 28.8% and 8.9% of subjects respectively, while NNRTI primary mutations K103N/S, G190A, and Y181C were found in 21.0%, 14.6%, and 10.9% of subjects.

Discussion: Similar M184 V/I predominance trends (81.2%) have been reported in Uganda.

Discussion: The fact that 3TC is a backbone for most Kenyan ART-regimens explains this predominance of M184 V/I.

Transmitted drug resistance to Tenofovir/Emtricitabine among persons with newly diagnosed HIV infection in Shenyang city, Northeast China from 2016 to 2018.

PMID: 34243716 2021 BMC infectious diseases

Abstract: The TDF/FTC DRMs included K65R (8/13), M184I/V (5/13), and Y115F (2/13).

Result: K65R is known to confer high-level resistance to TDF and intermediate-level resistance to FTC, while M184I/V confers high-level resistance to FTC and 3TC and low-level resistance to abacavir (ABC).

Result: The mutations included K65R (61.5%, 8/13), M184I/V (38.5%, 5/13), and Y115F (2/13).

Filtrator